Adherence to the standard dose of imatinib, rather than dose adjustment based on its plasma concentration, is critical to achieve a deep molecular response in patients with chronic myeloid leukemia

作者：Yoshida Chikashi; Komeno Takuya; Hori Mitsuo; Kimura Tomofumi; Fujii Masami; Okoshi Yasushi; Suzukawa Kazumi; Chiba Shigeru; Hasegawa Yuichi; Mukai Harumi Yamamoto; Ito Takayoshi; Shimizu Seiichi; Kamoshita Masaharu; Kudo Daisuke; Shinagawa Atsushi; Chikatsu Norio; Monma Yuriko; Watanabe Norimichi; Kojima Hiroshi^*

来源：International Journal of Hematology, 2011, 93(5): 618-623.

DOI：10.1007/s12185-011-0838-3

• Chronic myeloid leukemia
• Imatinib
• Plasma concentration
• Molecular response

The correlation between imatinib (IM) trough plasma concentration (Cmin) and clinical response was assessed in patients with chronic-phase chronic myeloid leukemia. The Cmin correlated with neither the achievement of complete cytogenetic response (977 vs. 993 ng/ml, P = 0.48) nor a major molecular response (1,044 vs. 818 ng/ml, P = 0.17). Although this was significantly higher in patients with complete molecular response (CMR) than in those without (1,430 vs. 859 ng/ml, P = 0.04), the difference was not significant in the sub-population treated with a standard dose of IM (400 mg/day). Finally, multivariate analysis showed that the IM standard dose, but not Cmin, was predictive of the achievement of CMR. We thus suggest that, in practical clinics at least, adherence to the standard dose is the most important factor for the achievement of CMR.

• 出版日期2011-5